StockCIK 1743881

BridgeBio Pharma, Inc. (BBIO): Insider Trades and Fund Holdings

In the past 12 months, BridgeBio Pharma, Inc. insiders reported 0 open-market purchases worth $0 and 3 sales worth $4.42M; 3 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$4.42MSold by insiders, 12 months

3Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 21, 2026.

Recent BBIO insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Sep 21	Sep 17	Neil KumarCEO	CEO (ind.)	▼ SELL10b5-1	10,000	69.08	$691K	−2.0%	Form 4 ↗
Aug 20	Aug 18	Neil KumarCEO	CEO	▼ SELL10b5-1	34,980	82.53	$2.89M	−13%	Form 4 ↗
Aug 20	Aug 19	Neil KumarCEO	CEO (ind.)	▼ SELL10b5-1	10,000	84.03	$840K	−1.9%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Neil Kumar	CEO	0	$0	3	$4.42M	Sep 21, 2026

Tracked funds that report BBIO

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Viking Global Investors	Q2 2026	9,949,219	$741.0M	2.11%	▼ −16.0%
Renaissance Technologies	Q2 2026	856,846	$63.8M	0.09%	▲ +134.3%
Bridgewater Associates	Q2 2026	448,143	$33.4M	0.14%	▲ +72.7%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →